Altimmune Inc. [ALT] stock Resumed by Jefferies analyst, price target now $30


Altimmune Company [NASDAQ: ALT] The stock went on an upward trajectory, up more than 5.20% on Thursday, which is a one-week price drop of less than -7.23%. Company report on September 14, 2022 that Altimmune reported significant reductions in liver fat content and body weight in a Phase 1b 12-week clinical trial of Pemvidutide in subjects with NAFLD.

Top 5 cheap stocks to own right now

While finding safe stocks with the potential for huge gains isn’t always easy, we’ve found a few that can pay off well. In fact, within our report, Top 5 cheap stocks to own right nowIn this article, we have identified five stocks that we believe can increase in value even if you have $1,000 to invest.

Register here to get a free report now. .

sponsored by

All three pimfidotide dose groups (1.2 mg, 1.8 mg, 2.4 mg) achieved the primary endpoint of relative and absolute reductions in liver fat, with a relative reduction of 68.5% in liver fat content in subjects who received the 1.8 mg dose at 12 weeks of treatment.

Mean weight loss of 4.9% (placebo rate 4.7%) in subjects without diabetes who received the 1.8 mg dose at 12 weeks of treatment.

Over the past 12 months, ALT stock is down -12.11%. Altimmune Inc stock’s 1-year forecast is for a potential rise of 53.74. The average equity rating for ALT stock is currently 1.70, and it trades more like a bullish pattern in the stock market.

The market capitalization per share was $688.99 million, with 47.50 million shares outstanding and 46.72 million shares in the current float. Compared to an average trading volume of 2.60 million shares, ALT stock reached a trading volume of 3,079,069 on the last trading day, which is why market watchers consider the stock to be active.

A teacher’s opinion of Altimmune Inc. [ALT]:

Based on careful, fact-backed analysis by Wall Street experts, the current consensus on ALT’s stock price target is $28.86 per share. Target price analysis and stock performance are usually carefully studied by market experts, and the current Wall Street consensus for ALT stock is a set recommendation at 1.70. This rating represents a strong buy recommendation, on a scale of 1 to 5, where 5 means strong sell, 4 represents sell, 3 represents hold, and 2 indicates buy.

Jefferies made an estimate for Altimmune Inc stock. , retaining their opinion of the stock as Buy, with their previous recommendation on December 29, 2021. While these analysts held the previous recommendation, HC Wainwright raised its buy target. The new note about price target was released on June 02, 2021, which is the official target price for Altimmune Inc stock. Previously, the target price had received another increase to $36, while Guggenheim analysts maintained a buy rating on ALT stock.

The Average True Range (ATR) is set by Altimmune Inc. at 1.99, with the price-to-sales ratio for ALT stock in the past 12-month period being 196.86. The price-to-book ratio for the last quarter was 3.26, with the price-to-cash per share for the same quarter set at 3.58.

ALT stock performance analysis:

Altimmune Company [ALT] It fell into the red at the end of last week, fell in a negative trend and fell by -7.23. With this latest performance, ALT shares are down -27.56% over the past four-week period, as well as down 94.32% over the past six months — not to mention a -12.11% drop in the last year of trading.

Overbought and oversold stocks can be easily tracked by the Relative Strength Index (RSI), where an RSI result of over 70 is overbought, and any price below 30 indicates oversold conditions. The RSI of 50 represents neutral momentum in the market. The current RSI for ALT stock for the last two weeks was set at 36.92, with the RSI for the last one trading at 30.88, and the three-week RSI at 41.88 for Altimmune Inc. [ALT]. The current moving average for the last 50 trading days of this stock is 15.47, while it recorded at 13.03 for the last trading week, and 9.37 for the last 200 days.

An insight into the fundamentals of Altimmune Inc:

Operating margin for any stock indicates how profitable the investment is, and Altimmune Inc. [ALT] The current equity operating margin is -1937.35 and the total margin is +87.50. Net margin reported to Altimmune Inc. Currently at -2201.43.

The return on equity for this stock fell to -45.69, with the return on assets remaining at -41.85.

The liquidity data of Altimmune Inc. Interesting too, with the quick ratio at 14.10 and the current ratio at 14.10.

Altimmune Company [ALT] Insiders’ position details

There are currently approximately $543 million, or 81.80% of ALT’s stock, in the hands of institutional investors. The three largest ALT owners are: TANG CAPITAL MANAGEMENT LLC with 3,600,450 ownership, which is approximately 39.892% of the company’s market capitalization and about 0.60% of the total institutional ownership; NUVEEN ASSET MANAGEMENT, LLC, owns 3,064,280 shares with an approximate value of $40.91 million in ALT stock; and CORMORANT ASSET MANAGEMENT, LP, currently with $40.05 million in ALT stock with nearly new ownership of the company’s market value.

Positions in Altimmune Inc shares increased. held by institutional investors at the end of August and at the time of the August report, as 67 institutional owners consolidated their positions in Altimmune Inc. [NASDAQ:ALT] About 14,229,689 shares. The number of investors decreased by 63 investors by about 7,338,554 shares, while 12 investors held positions with 19,132,272 shares. The said changes put institutional holdings at 40,770,515 shares, according to the latest report from the Securities and Exchange Commission. ALT stock had 40 new institutional investments totaling 10,158,819 shares, while 31 institutional investors sold deals totaling 997,234 shares during the same period.

Leave A Reply

Your email address will not be published.